Who are RT+CDDP/5-FU's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eloxatin, Carboplatin or Cisplatin, Carboplatin Injection, Oxaliplatin;Capecitabine, Oxaliplatin (OXAL), Platinum-based doublet chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rt-cddp-5-fu.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

RT+CDDP/5-FU — Competitive Intelligence Brief

RT+CDDP/5-FU (RT+CDDP/5-FU) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapy. Area: Oncology.

phase 3 Platinum-based chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

RT+CDDP/5-FU (RT+CDDP/5-FU) — Associazione Volontari Pazienti Oncologici. RT+CDDP/5-FU is a combination chemotherapy regimen that works by inhibiting DNA replication and interfering with DNA repair, ultimately leading to cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RT+CDDP/5-FU TARGET	RT+CDDP/5-FU	Associazione Volontari Pazienti Oncologici	phase 3	Platinum-based chemotherapy
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
Carboplatin or Cisplatin	Carboplatin or Cisplatin	Second Hospital of Shanxi Medical University	marketed	Platinum-based chemotherapy agent	DNA
Carboplatin Injection	Carboplatin Injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Platinum-based chemotherapy agent	DNA
Oxaliplatin;Capecitabine	Oxaliplatin;Capecitabine	Hebei Medical University	marketed	Platinum-based chemotherapy combination; antimetabolite	DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU)
Oxaliplatin (OXAL)	Oxaliplatin (OXAL)	Memorial Sloan Kettering Cancer Center	marketed	Platinum-based chemotherapy agent	DNA
Platinum-based doublet chemotherapy	Platinum-based doublet chemotherapy	The First Hospital of Hebei Medical University	marketed	Platinum-based chemotherapy doublet	DNA (platinum-DNA adducts)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based chemotherapy class)

Jiangsu HengRui Medicine Co., Ltd. · 2 drugs in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 2 drugs in this class
Holy Name Medical Center, Inc. · 2 drugs in this class
Sun Yat-sen University · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Centre Oscar Lambret · 1 drug in this class
Centre Leon Berard · 1 drug in this class
AstraZeneca · 1 drug in this class
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · 1 drug in this class
CatalYm GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RT+CDDP/5-FU — Competitive Intelligence Brief. https://druglandscape.com/ci/rt-cddp-5-fu. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab